{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=29&sponsor=Boehringer+Ingelheim",
    "query": {
      "sponsor": "Boehringer Ingelheim",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 673,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=30&sponsor=Boehringer+Ingelheim&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=28&sponsor=Boehringer+Ingelheim&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T10:18:00.662Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01539421",
      "title": "Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Use of Home exercise computer program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Trinity Health Of New England",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-06",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2012-02-28",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539421"
    },
    {
      "nct_id": "NCT00804479",
      "title": "The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "No intervention.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 222,
      "start_date": "2002-01",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-21",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00804479"
    },
    {
      "nct_id": "NCT02788474",
      "title": "Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "nintedanib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 347,
      "start_date": "2016-06-09",
      "completion_date": "2018-06-08",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 8,
      "location_summary": "Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788474"
    },
    {
      "nct_id": "NCT06962839",
      "title": "A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "BI 1815368",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-06-05",
      "completion_date": "2028-03-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06962839"
    },
    {
      "nct_id": "NCT05376800",
      "title": "A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "BI 907828 (Brigimadlin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-11-30",
      "completion_date": "2025-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05376800"
    },
    {
      "nct_id": "NCT01164501",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 741,
      "start_date": "2010-07",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 18,
      "location_summary": "Anaheim, California • Lomita, California • Plantation, Florida + 15 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01164501"
    },
    {
      "nct_id": "NCT04399837",
      "title": "A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Pustular Psoriasis"
      ],
      "interventions": [
        {
          "name": "Spesolimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 123,
      "start_date": "2020-06-04",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 2,
      "location_summary": "Auburn Hills, Michigan • St Louis, Missouri",
      "locations": [
        {
          "city": "Auburn Hills",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04399837"
    },
    {
      "nct_id": "NCT01257230",
      "title": "Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium Respimat low dose",
          "type": "DRUG"
        },
        {
          "name": "placebo Respimat",
          "type": "DRUG"
        },
        {
          "name": "tiotropium Respimat high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 398,
      "start_date": "2010-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-09-05",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 8,
      "location_summary": "Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257230"
    },
    {
      "nct_id": "NCT00808067",
      "title": "RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "dabigatran dose 1",
          "type": "DRUG"
        },
        {
          "name": "dabigatran dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5897,
      "start_date": "2008-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 216,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Lake Havasu City, Arizona + 185 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00808067"
    },
    {
      "nct_id": "NCT00517192",
      "title": "Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tipranavir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-14",
      "last_synced_at": "2026-10-18T10:18:00.662Z",
      "location_count": 9,
      "location_summary": "Beverly Hills, California • Fort Lauderdale, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00517192"
    }
  ]
}